Pharma Pulse: Patients Struggle to Identify Safe Online Pharmacies, as Novo Nordisk Launches Access Offers
In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access and industry strategy.
2m Nov 19, 2025
2m
Pharma Pulse: Rural Vaccine Gaps, Semaglutide Organ-Protective Benefits, and Amazon Pharmacy’s Urgent Care Expansion Shape Healthcare Outlook
A review of COVID-19 vaccine access inequities, emerging cardioprotective data for semaglutide, and Experity’s integration with Amazon Pharmacy highlights the shifting dynamics of patient access, clinical innovation, and digital-first care delivery in today’s Pharma Pulse.
3m Nov 18, 2025
3m
Pharma Pulse: Young Adults Skip Cholesterol Care, as Pharmacy Access Gaps Widen and Crypto Enters the Prescription Market
This episode of Pharma Pulse discusses how new analysis shows poor treatment and monitoring rates among young adults with high cholesterol, while national efforts ramp up to identify pharmacy deserts—and one US pharmacy becomes the first to accept cryptocurrency for prescriptions.
3m Nov 17, 2025
3m
Pharma Pulse: FDA Advances New Approval Pathway, as Obesity Care and Metabolic Treatments Gain Momentum
This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity and metabolic health care.
2m Nov 14, 2025
2m
Pharma Pulse: FDA Appoints Richard Pazdur as CDER Director Amid 340B Tensions and Novartis Expansion
This episode of Pharma Pulse discusses how Dr. Richard Pazdur’s appointment signals a new era for FDA drug evaluation, why hospitals are opposing the government’s 340B pilot program, and how Novartis is expanding its US manufacturing footprint with a new radioligand therapy facility in California.
2m Nov 13, 2025
2m
Pharma Pulse: HHS Updates Menopausal Hormone Therapy Labels, as SGLT2 Inhibitors Show Broader Kidney and Heart Benefits
This episode of Pharma Pulse explores how regulators modernize safety information for hormone therapy, new data that reinforces SGLT2 inhibitors’ clinical value, and Arsenal Capital expanding its life sciences logistics portfolio with the ThermoSafe acquisition.
2m Nov 12, 2025
2m
Pharma Pulse: New Research and Policy Moves Shape Pharma Landscape
This episode of Pharma Pulse explores a major review finding no link between maternal acetaminophen use and autism or ADHD, CMS launching initiatives to cut Medicaid drug costs, and Eli Lilly expanding its gene therapy collaborations.
2m Nov 11, 2025
2m
Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza
This episode of Pharma Pulse discusses FDA’s growing National Priority Voucher initiative, fresh data on oral semaglutide’s cardiometabolic impact, and Mark Cuban’s latest drug addition that signals key shifts in innovation, access, and affordability across the pharmaceutical landscape.
2m Nov 10, 2025
2m
Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada
This episode of Pharma Pulse discusses Novartis’ $12 billion acquisition of Avidity Biosciences to expand its RNA therapeutics portfolio, and Trump’s proposed 10% tariff increase on Canadian imports that could disrupt pharma supply chains.
2m Oct 28, 2025
2m
Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing
This episode of Pharma Pulse discusses new research linking cholesterol imbalance in obesity to higher depression risk, Eli Lilly’s acquisition of Aderum Biotechnologies to strengthen its neuroscience pipeline, and Cambrex’s $120 million investment to boost US API manufacturing capacity.
3m Oct 27, 2025
3m
Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models
This episode of Pharma Pulse covers Alkermes’ acquisition of Avadel Pharmaceuticals to expand its portfolio, BioNTech’s public exchange offer for CureVac to strengthen its mRNA pipeline, and a new report revealing how US medical device manufacturers are adopting digital-first models to boost compliance and patient engagement.
3m Oct 24, 2025
3m
Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network
This episode of Pharma Pulse covers MJH Life Sciences’ acquisition of BPD Healthcare to deepen its reach into hospitals and health systems, investor reaction to Novo Nordisk’s recent board changes, and Mark Cuban’s latest partnership expanding his Cost Plus Drugs platform to disrupt traditional pharmacy pricing models.
3m Oct 23, 2025
3m
Pharma Pulse: Telehealth Medication Abortion Requests Surge, FDA Expedites Tzield Review, and New Biopharma Air Network Launches
This episode of Pharma Pulse discusses new data showing a post-Dobbs surge in telehealth medication abortion requests, the FDA’s expedited review of Tzield under its new National Priority Voucher Program, and the launch of a dedicated biopharma air logistics network by Frontier Scientific Solutions and ATSG.
3m Oct 22, 2025
3m
Pharma Pulse: Amazon Enters Weight-Loss Drug Market, Merck Expands US Manufacturing, and FDA Approves Tezspire for Chronic Sinusitis
This episode of Pharma Pulse covers Amazon and WeightWatchers’ partnership to deliver FDA-approved weight-loss medications, Merck’s new biomanufacturing center of excellence in Virginia, and the FDA’s first-ever approval of a TSLP-targeting biologic, Tezspire, for chronic rhinosinusitis with nasal polyps.
2m Oct 21, 2025
2m
Pharma Pulse: Severe COVID-19 Raises Stroke Risk in Asthma Patients, Parents Divided on Vaccine Policies, and 2026 Medicare Rankings Revealed
This episode of Pharma Pulse discusses new research linking severe COVID-19 to increased stroke risk among asthma patients, a KFF poll showing divided parental support for vaccine-related agendas, and US News & World Report’s 2026 list of top Medicare Advantage and Part D plan providers.
3m Oct 20, 2025
3m
Pharma Pulse: Cancer Care Gaps Persist, Physician Pay Hits Record Highs, and AstraZeneca Expands Texas Manufacturing
This episode of Pharma Pulse discusses new research revealing persistent disparities in women’s cancer outcomes, record-high physician pay amid steady productivity, and AstraZeneca’s major Texas expansion to double production of its hyperkalemia treatment, Lokelma.
3m Oct 17, 2025
3m
Pharma Pulse: FDA Approves One-Minute HIV Test, US Delays Pharma Tariffs, and CVS Acquires 600 Rite Aid Stores
This episode of Pharma Pulse covers the FDA’s approval of a rapid one-minute HIV self-test, the US government’s decision to delay tariffs on pharmaceutical exports from Singapore, and CVS Pharmacy’s acquisition of more than 600 Rite Aid stores across three states to expand its community health footprint.
3m Oct 16, 2025
3m
Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site
This episode of Pharma Pulse covers the nationwide Kaiser Permanente strike involving more than 40,000 healthcare workers, Takeda’s new AI-driven antibody discovery partnership with Nabla Bio, and the FDA’s OAI designation for Novo Nordisk’s Bloomington manufacturing facility.
3m Oct 15, 2025
3m
Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint
This episode of Pharma Pulse covers how recent CDC layoffs are fueling concerns about disease surveillance, Ypsomed’s new autoinjector manufacturing site in North Carolina, and Lupin’s $250 million investment to build a respiratory and specialty drug facility in Florida.
3m Oct 14, 2025
3m
Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics
This episode of Pharma Pulse covers how Mark Cuban’s direct-to-consumer pharmacy is challenging traditional drug pricing models, AstraZeneca’s $4.5 billion investment to expand its Virginia manufacturing site, and Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics to advance RNA-based medicines.
3m Oct 13, 2025
3m
Pharma Pulse: CDC Updates Vaccine Guidance, GLP-1s Linked to Imaging Challenges, and Novo Nordisk Loses Inflation Reduction Act Appeal
This episode of Pharma Pulse covers the CDC’s new individualized approach to COVID-19 vaccination and changes to chickenpox guidance for toddlers, new research showing how GLP-1 therapies can interfere with PET-CT imaging results, and the Third Circuit Court’s rejection of Novo Nordisk’s IRA challenge.
3m Oct 10, 2025
3m
Pharma Pulse: FDA Expands Pediatric UC Treatment Options, AstraZeneca and Algen Partner in Neurology, and Peli BioThermal Boosts Cold Chain Capabilities
This episode of Pharma Pulse covers the FDA’s approval of golimumab for pediatric ulcerative colitis, AstraZeneca’s new multi-target neuroscience partnership with Algen, and Peli BioThermal’s acquisition of Evo to strengthen its global cold chain portfolio.
3m Oct 09, 2025
3m
Pharma Pulse: Study Links Early Obesity to Postpartum Diabetes Risk, Amgen Launches AmgenNow, and Eli Lilly Strengthens Global Supply Chain
This episode of Pharma Pulse covers new research showing how obesity at age 20 increases postpartum diabetes risk, Amgen’s new direct-to-consumer digital platform aimed at improving treatment access, and Eli Lilly’s $1 billion investment to strengthen manufacturing in India.
3m Oct 08, 2025
3m
Pharma Pulse: NIAID Whistleblower Controversy, ALS Linked to Autoimmunity, and Hospital Layoffs Accelerate Nationwide
This episode of Pharma Pulse covers allegations of retaliation against a former NIAID director following whistleblower complaints, new research suggesting ALS may be an autoimmune disease, and the wave of hospital layoffs affecting thousands of healthcare workers across the United States.
3m Oct 07, 2025
3m
Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage
This episode of Pharma Pulse covers the FDA’s quiet approval of the first generic mifepristone tablet, Takeda’s decision to discontinue cell therapy research programs, and SciSafe’s expansion of biopharma storage capacity with a new East Brunswick, New Jersey facility.
3m Oct 06, 2025
3m
Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High
This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.
3m Oct 03, 2025
3m
Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M
This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.
3m Oct 02, 2025
3m
Pharma Pulse: Trump Plans Direct-to-Patient Website, Gabapentin Prescriptions Surge, and Gene Therapy Slows Huntington’s Progression
This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.
2m Oct 01, 2025
2m
Pharma Pulse: Measles Vaccination Gaps Persist, FDA Approves Guselkumab for Children, and AbbVie Expands US Manufacturing
This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.
2m Sep 30, 2025
2m
Pharma Pulse: Drug Tariffs Threaten Access, Pediatric Flu Raises Vaccination Concerns, and AbbVie Files NDA for Tavapadon
This episode of Pharma Pulse covers the Trump administration’s 100% tariff on branded drug imports, new research linking pediatric influenza to neurological complications amid vaccination gaps, and AbbVie’s FDA submission for tavapadon, a potential new treatment for Parkinson’s disease.
2m Sep 29, 2025
2m
Pharma Pulse: Medicaid Cuts Threaten Childhood Coverage, Fixed-Dose Combo Reduces Heart Failure in Diabetes, and BMS Expands Sotyktu Access
This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.
2m Sep 26, 2025
2m
Pharma Pulse: CDC Expands COVID-19 Vaccine Guidance, Medicare Model Cuts Insulin Costs, and Lilly Invests in Houston Facility
This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.
3m Sep 25, 2025
3m
Pharma Pulse: FDA Examines Prenatal Acetaminophen Risks, GSK Files sNDA for Leucovorin, and Celltrion Buys Lilly Plant
This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.
3m Sep 24, 2025
3m
Pharma Pulse: CDC Shifts COVID-19 Vaccine Guidance, Pfizer Buys Metsera for Obesity Pipeline, and New Tech Targets GLP-1 Adherence
This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.
3m Sep 23, 2025
3m
Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping
This episode of Pharma Pulse covers the CDC’s decision to postpone changes to Hepatitis B vaccine guidance, new research showing value-based care improves visit frequency and consistency for seniors, and Takeda’s partnership with VELA to launch wind-powered transport for medicines.
3m Sep 22, 2025
3m
Pharma Pulse: GSK Invests $30B in US Manufacturing, GLP-1s Show Heart Benefits, and Roche Buys 89bio for Metabolic Pipeline
This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.
2m Sep 19, 2025
2m
Pharma Pulse: CDC Leadership Controversy, Physician Mental Health Challenges, and Eli Lilly’s $5B US Manufacturing Expansion
This episode of Pharma Pulse covers the former CDC director’s claim she was dismissed for refusing to prioritize ideology over evidence, new findings that physician mental health remains a serious concern, and Eli Lilly’s $5 billion investment in a new Virginia manufacturing plant to expand biologics production.
2m Sep 18, 2025
2m
Pharma Pulse: Parental Vaccine Hesitancy Grows, Federal Vaccine Committee Expands, and Healthcare Workforce Faces Retention Crisis
This episode of Pharma Pulse covers new data showing 1 in 6 US parents are delaying or skipping childhood vaccinations, Secretary Robert F. Kennedy Jr.’s move to expand a federal vaccine advisory committee, and survey findings that more than half of healthcare workers are considering leaving their current roles.
2m Sep 17, 2025
2m
Pharma Pulse: Rural Hospitals Seek $50B Lifeline, Vaccination Gaps Found in Celiac Patients, and Novartis Signs $5.7B Licensing Deal
This episode of Pharma Pulse covers healthcare advocates’ push for a $50 billion Rural Health Transformation Program, new research showing pneumococcal vaccination gaps among adults with celiac disease, and Novartis’ $5.7 billion licensing agreement with Monte Rosa Therapeutics for protein degrader therapies.
2m Sep 16, 2025
2m
Pharma Pulse: FDA Accelerates Non-Opioid Pain Drug Development, FTC Targets Non-Competes in Healthcare, and DHL Expands Last-Mile Logistics
This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.
3m Sep 15, 2025
3m
Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal
This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.
3m Sep 12, 2025
3m
Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs
This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.
3m Sep 11, 2025
3m
Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence
This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.
3m Sep 10, 2025
3m
Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program
This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.
3m Sep 09, 2025
3m
Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits
This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.
3m Sep 08, 2025
3m
Pharma Pulse: Trump Appeals Tariff Ruling, Sanofi Shares Slide on Trial Miss, and COVID-19 Alters Pneumococcal Mortality
This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.
3m Sep 05, 2025
3m
Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes
This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.
3m Sep 04, 2025
3m
Pharma Pulse: FDA Approves Sanofi’s Wayrilz, OTC Triptans Show Public Health Gains, and Biosimilar Rules Streamlined
This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.
3m Sep 03, 2025
3m
Pharma Pulse: Flu Vaccination Rates Improve, AI Powers RNA Therapeutics, and Statin Intolerance Spurs Self-Medication Risks
This episode of Pharma Pulse covers rising influenza vaccination rates among historically underserved populations, a new Circurna–GATC Health partnership using AI to advance circular RNA therapies, and fresh research showing many statin-intolerant patients are self-medicating despite limited benefits for lowering LDL cholesterol.
3m Sep 02, 2025
3m
Pharma Pulse: Child Vaccines Show Adult Protection, Lilly Pauses Mounjaro Shipments, and FDA Rejects Lytenava Resubmission
This episode of Pharma Pulse covers new evidence that childhood PCV10 vaccines indirectly protect unvaccinated adults, Eli Lilly’s pause in UK Mounjaro shipments following a major price hike, and the FDA’s Complete Response Letter to Outlook Therapeutics’ resubmission for Lytenava in wet AMD.
3m Sep 01, 2025
3m